Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

631
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
631
Methods of Documentation V: CBE01:23

Methods of Documentation V: CBE

1.4K
Charting by Exception, or CBE, is a method of documentation used in healthcare, particularly in nursing, that focuses on documenting only significant or abnormal findings rather than recording every detail. This approach aims to streamline the documentation process, improve efficiency, and ensure that healthcare providers can quickly identify deviations from normalcy in patient assessments.
In CBE, healthcare professionals establish predefined standards of practice that define what constitutes...
1.4K
Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

358
The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
358
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

734
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
734
Factors Influencing Attraction II: Physical Attraction01:21

Factors Influencing Attraction II: Physical Attraction

458
Physical attractiveness plays a crucial role in shaping interpersonal attraction, influencing first impressions, social interactions, and long-term relationship dynamics. Psychological research consistently demonstrates that attractiveness affects social evaluations and behavioral outcomes in various contexts.Influence on Social InteractionsResearch has shown that individuals perceived as physically attractive often experience preferential treatment in social and professional settings. One...
458
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

97
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Simulation of long-term lecanemab treatment effect on Alzheimer's disease progression.

Alzheimer's & dementia (New York, N. Y.)·2026
Same author

Subgroup identification via Interaction Tree and Mixed Model for Repeated Measures with application to Alzheimer's disease.

Biometrics·2026
Same author

Phase 2 Futility Trials in Alzheimer Disease and Mild Cognitive Impairment: A Cohort Analysis of the ADNI Data Set.

Neurology·2026
Same author

Application of the 2024 McDonald Criteria in Individuals With Nonspecific Symptoms or Incidental Imaging Findings in a Multicenter Study.

Neurology·2026
Same author

Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study.

Lancet (London, England)·2026
Same author

Men's health research priorities in men with multiple sclerosis.

Multiple sclerosis journal - experimental, translational and clinical·2026

Related Experiment Video

Updated: May 6, 2026

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents
07:05

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents

Published on: September 10, 2018

5.2K

Cost-effectiveness analyses: Beauty and the beast?

Gary R Cutter1, Guoqiao Wang

  • 1Department of Biostatistics, UAB School of Public Health, Birmingham, AL.

Neurology. Clinical Practice
|November 1, 2013
PubMed
Summary
This summary is machine-generated.

This article explains how to interpret cost-effectiveness and decision analysis studies in healthcare. Understanding these analyses is crucial for balancing patient care costs with therapeutic benefits.

More Related Videos

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
06:16

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

1.2K
E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
06:28

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

8.1K

Related Experiment Videos

Last Updated: May 6, 2026

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents
07:05

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents

Published on: September 10, 2018

5.2K
Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
06:16

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

1.2K
E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
06:28

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

8.1K

Area of Science:

  • Health Economics
  • Clinical Decision Making
  • Medical Policy

Background:

  • Healthcare systems face increasing pressure to manage costs while ensuring quality patient care.
  • Cost-effectiveness and decision analysis studies are becoming essential tools for evaluating medical interventions.
  • Understanding these complex analyses is vital for clinicians, policymakers, and researchers.

Purpose of the Study:

  • To provide a guide on interpreting cost-effectiveness and decision analysis studies.
  • To highlight key considerations for evaluating the validity and applicability of such studies.
  • To aid stakeholders in making informed decisions regarding healthcare resource allocation.

Main Methods:

  • The article reviews common methodologies used in cost-effectiveness and decision analysis.
  • It emphasizes the importance of understanding the underlying models and data interpretation.
  • Key approaches used by policymakers and researchers are summarized.

Main Results:

  • Cost-effectiveness studies provide a framework for comparing the value of different healthcare interventions.
  • Decision analysis models help in evaluating complex choices with uncertain outcomes.
  • Systematic evaluation of cost versus therapeutic benefits is crucial.

Conclusions:

  • Interpreting cost-effectiveness and decision analysis studies requires careful consideration of their models and data.
  • These studies are increasingly important for navigating the financial pressures in healthcare.
  • A systematic approach aids in understanding the balance between healthcare costs and patient benefits.